[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cough\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cough":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,48,76,100,130,153,176,204,239,267,296,322,353,376,399,424,448,471,497,523,552,576],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100642256","phase-4-oliceridine-vs-sufentanil-for-cough-during-anesthesia-induction-100642256",false,"NCT07660380","Oliceridine vs Sufentanil for Cough During Anesthesia Induction","Oliceridine vs Sufentanil for Cough During General Anesthesia Induction: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 18 to 99 years.\n* American Society of Anesthesiologists (ASA) physical status classification I, II, or III.\n* Body mass index (BMI) between 18.5 and 28.0 kg\u002Fm².\n* Scheduled for elective surgery under general anaesthesia.\n* Able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Preoperative upper respiratory tract infection symptoms (e.g., cough, expectoration, or fever) or a history of bronchial asthma or other conditions associated with increased airway reactivity.\n* Severe cardiovascular disease (e.g., uncontrolled hypertension, recent myocardial infarction, or serious arrhythmia) or hepatic or renal dysfunction.\n* Long-term opioid use, defined as continuous opioid use for more than 2 weeks within the 3 months prior to surgery.\n* Known hypersensitivity to any study drug or anaesthetic agent used in this protocol.\n* Anticipated difficult airway requiring awake intubation.\n* Pregnancy or breastfeeding.","ALL","18 Years","99 Years",{"count":20,"type":21},62,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Sufentanil is the most widely used opioid analgesic for general anaesthesia induction; however, rapid intravenous bolus injection frequently triggers sufentanil-induced cough (SIC). In high-risk patients, SIC can cause abrupt elevation of intracranial and intraocular pressure and severe haemodynamic instability, posing a meaningful safety risk during the induction period.\n\nOliceridine, the first G protein-biased μ-opioid receptor agonist approved by the Food and Drug Administration in 2020, provides analgesia through μ-receptor activation while substantially reducing β-arrestin-2 recruitment. This biased signalling profile is hypothesised to raise the excitation threshold of airway C-fibres and thereby reduce the incidence of cough.\n\nThis prospective, single-centre, randomised, double-blind, parallel-group controlled trial directly compares oliceridine with sufentanil for general anaesthesia induction with respect to cough incidence, cough severity, haemodynamic responses, and perioperative safety, with the aim of providing evidence-based guidance for opioid selection during induction.",[27,28],"Cough","Anesthesia",[30,31,32,33,34],"Oliceridine","Sufentanil","Sufentanil-induced cough","G protein-biased agonist","Anesthesia induction","NOT_YET_RECRUITING","2026-06-18",{"date":38,"type":39},"2026-06-23","ACTUAL",{"date":41,"type":21},"2026-06-22",{"date":43,"type":21},"2026-07-01",{"name":45,"class":46},"Shiyou Wei","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":47},"100560656","usefulness-and-feasibility-of-ultrasound-in-office-laryngology-procedures-100560656","NCT06579989","Usefulness and Feasibility of Ultrasound in Office Laryngology Procedures","Usefulness and Feasibility of Ultrasound in Office Laryngology Procedures: A Pilot Study","Inclusion Criteria:\n\n* US-Guided Injection for Neurogenic Cough:\n\n  1. Age over 18 years\n  2. Recommended to undergo superior laryngeal nerve block\n* US-Assessment of Superior Laryngeal Nerve Anatomy\n\n  1. Age over 18 years\n  2. No cough complaints\n* US-Assessment of Injectate Volume:\n\n  1. Documentation of unilateral vocal fold paresis\u002Fparalysis or atrophy\n  2. Age over 18 years\n  3. Recommended to undergo injection laryngoplasty\n* US-Assessment of Swallow:\n\n  1. Age over 18 years\n  2. Presents with swallowing complaints\n* US-Assessment of Normal Swallow:\n\n  1. Age over 18 years\n  2. Presents without swallowing complaints\n* US-Assessment of Voice:\n\n  1. Age over 18 years\n  2. Undergoing evaluation of voice problems\n\nExclusion Criteria:\n\n1. Age under 18 years and over 99 years\n2. Open neck wound including tracheostomy",true,{"count":57,"type":21},200,[59],"NA","Investigators will assess the usefulness of using ultrasound in office procedures for laryngology interventions. Participants who qualify will be adults who are undergoing superior laryngeal nerve block, injection laryngoplasty, swallowing evaluation, voice evaluation and voice therapy.",[27,62,63,64,65,66],"Vocal Cord Atrophy","Vocal Cord Paresis","Vocal Cord Paralysis","Dysphagia","Dysphonia","2026-06-12",{"date":69,"type":39},"2026-06-16",{"date":71,"type":21},"2027-01",{"date":73,"type":21},"2030-01",{"name":75,"class":46},"Weill Medical College of Cornell University",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":47},"100460251","stimulation-of-the-larynx-to-treat-unexplained-chronic-cough-100460251","NCT05273190","Stimulation of the Larynx to Treat Unexplained Chronic Cough","Vibrotactile Stimulation of the Larynx to Treat Unexplained Chronic Cough","Inclusion Criteria:\n\n* Adults aged 18-88\n* \\>8 weeks of cough\n* Cough visual analogue scale (VAS): Rating of 30 or greater on a 0-100 cough severity scale\n* Ability to provide informed consent and independently complete questionnaires\n* Ability to read and speak English\n\nExclusion Criteria:\n\n* Electronic implants (e.g., pacemaker)\n* Currently doing speech therapy for cough\n* Contraindications to safe or effective VTS device use\n* No regular access to wifi internet Neuromuscular impairment that may affect cough\u002Flaryngeal sensation and\u002For function (e.g., multiple system atrophy, Parkinson, CVA, vocal fold paralysis or paresis)\n* Untreated carotid disease\n* BMI \\> 40 (for transmission of VTS through soft tissue)\n* Current or recent (quit \\\u003C 3 months ago) smoking\n* Known currently infectious cause for cough (e.g., TB, pertussis, COVID)\n* History of known or suspected aspiration pneumonia\n* Diagnosis or clinical suspicion of chronic obstructive pulmonary disease (COPD)\n* Diagnosis or clinical suspicion of interstitial lung disease (ILD)\n* Unmanaged reflux\n* Unmanaged allergies\u002Fpostnasal drip","88 Years",{"count":85,"type":21},60,[59],"Researchers will test the effect of non-invasive vibrotactile stimulation of the larynx on symptom severity of unexplained chronic cough.",[27],[90],"Chronic cough","RECRUITING",{"date":93,"type":39},"2026-06-15",{"date":95,"type":39},"2021-07-13",{"date":97,"type":21},"2027-06-30",{"name":99,"class":46},"University of Minnesota",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":55,"sex":16,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":47},"100530718","does-the-coaching-function-improve-the-learning-of-mechanical-in-exsufflation-mi-e-in-paediatric-subjects-100530718","NCT06190431","Does the Coaching Function Improve the Learning of Mechanical In-exsufflation (MI-E) in Paediatric Subjects?","MI-Ecoaching","Part 1:\n\n* Inclusion criteria\n\n  * Age 6-12 (F\u002FM)\n  * Acceptance of consent (child + 2 parents)\n  * Non-smoker\n  * Speak and understand French\n  * Schooling in mainstream education\n* Exclusion criteria\n\n  * Comorbidities: congenital heart disease, chronic lung disease, immune deficiency, neuromuscular disease, neurological disease or multiple disabilities\n  * History or clinical signs of disease affecting lung function, recent lung infection, spinal or thoracic deformity.\n\nPart 2:\n\n* Inclusion criteria\n\n  * Age 6-12 (F\u002FM)\n  * Acceptance of consent (child + 2 parents)\n  * Non-smoker\n  * Speak and understand French\n  * Patient with a neuromuscular disease\n  * Able to perform the MI-E maneuver\n* Exclusion criteria\n\n  * Hemodynamic instability\n  * Current or recent pneumothorax\n  * Hemoptysis","6 Years","12 Years",{"count":110,"type":21},40,[59],"The use of mechanical insufflation-exsufflation (MI-E) in children with neuromuscular diseases (NMD) is recommended by international guidelines and societies and well documented. Many authors have shown that MI-E is safe and effective for airway clearance and has a significant benefit in reducing the duration of the airway clearance session in children with respiratory infections and atelectasis or in the postoperative period. However, its use in paediatrics is still poorly supervised and learning the technique is too often therapist- and\u002For patient-dependent. The use of a protocol or means of help to guide the initiation and learning of MI-E would allow better use, better adaptation of the settings and potentially better compliance with the treatment. The aim of this study is to test whether the use of a coaching module (playful visual stimulation) in addition to guidance by a physiotherapist improves the learning and effectiveness of the technique compared to guidance alone.This randomized controlled study will first include healthy children, aged 6 to 12 years, with no history or recent respiratory infection affecting lung function or other chronic diseases. In a second phase, the investigators will test the use of the learning process in children with neuromuscular diseases. The investigators hope that the results of this study will provide a better framework for the learning and effectiveness of MI-E. Furthermore, if the results are positive, this will allow better support for the use of MI-E in chronic treatments and help to ensure that this costly treatment for hospitals and public health is used efficiently.",[27,114,115],"Airway Clearance Impairment","Neuromuscular Diseases",[117,118,119,120],"Mechanical In-Exsufflation","Coaching","Cough Assistance","Pediatric","2026-05-29",{"date":123,"type":39},"2026-06-01",{"date":125,"type":39},"2023-11-20",{"date":127,"type":21},"2026-05-31",{"name":129,"class":46},"Cliniques universitaires Saint-Luc- Université Catholique de Louvain",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":139,"phases":4,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":47},"100411807","office-based-superior-laryngeal-nerve-block-for-treatment-of-neurogenic-cough-100411807","NCT04642352","Office-Based Superior Laryngeal Nerve Block for Treatment of Neurogenic Cough","Office-Based Superior Laryngeal Nerve (SLN) Block for Treatment of Neurogenic Cough","Inclusion Criteria:\n\n* Age 18 years or older\n* Ability of patients to speak and understand English\n* Ability for patients to consent for themselves\n* Cough for 8 weeks or greater, with suspected sensory neuropathic etiology of the cough. Inclusion based on history of preceding upper respiratory infection or other symptoms suggestive of irritable larynx such as cough in response to temperature changes, odors, scents\u002Fperfumes, tickle, irritation in the throat\u002Fparalaryngeal region, or talking.\n* Persistent cough despite treatment of ALL the major contributors of cough (items listed below would be done as part of a standard clinical workup for chronic cough and are not done specific to this study):\n\n  * Reflux disease treatment with one of the following: failure of two months of PPIs OR negative pH study\n  * Asthma: lack of response to at least one month of steroid inhaler\u002Fbronchodilator OR normal PFTs\u002Fnegative methacholine challenge + negative CXR\u002FCT\n  * Upper airway cough syndrome\u002FAllergic disease: lack of response to at least one month of antihistamines\u002Fdecongestants\u002Fnasal steroids OR negative allergy testing (skin or serum) OR lack of response to at least one year of immunotherapy\u002Fallergy shots\n\nExclusion Criteria:\n\n* Age less than 18 years\n* Patients unable or unwilling to provide informed consent\n* Known etiology to cough other than sensory neuropathy (e.g., reflux disease, asthma, allergic rhinitis, chronic obstructive pulmonary disease)\n* Addition of new neuromodulators at the time of the injection. Patients who were already being treated with neuromodulators for their cough (e.g., gabapentin, amitriptyline) will not be excluded provided their dose remains constant.\n* Nissen fundoplication within the last year\n* Smoking history within last 5 years\n* Allergy to bupivacaine or Kenalog-40",{"count":138,"type":21},50,"OBSERVATIONAL","The purpose of this study is to evaluate if office-based injection of a local anesthetic\u002Fsteroid combination at the area of one superior laryngeal nerve can decrease cough frequency and alleviate symptoms of chronic cough in patients with neurogenic cough.",[27],[143],"chronic cough","2026-05-04",{"date":146,"type":39},"2026-05-08",{"date":148,"type":39},"2022-01-03",{"date":150,"type":21},"2026-10",{"name":152,"class":46},"University of Alabama at Birmingham",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":47},"100618379","phase-4-evaluation-of-treatments-for-dry-or-productive-cough-100618379","NCT07330856","Evaluation of Treatments for Dry or Productive Cough","Evaluation of Treatments for Recent Dry or Productive Cough Accompanying Benign Viral Rhinopharyngeal Infectious Episodes.","SPRATO","Inclusion Criteria:\n\n* Male or female,\n* Aged 18 to 65 years,\n* Presenting with an acute dry or productive cough for less than 3 weeks, associated with one of the following viral conditions: Acute viral rhinitis, Acute viral rhinopharyngitis, Acute viral tonsillitis, Acute viral pharyngitis \u002F tonsillitis,\n* For patients with suspected pharyngitis\u002Ftonsillitis: McIsaac score \\\u003C 2 or a negative rapid antigen detection test for Group A beta-hemolytic Streptococcus,\n* Effective contraception for female patients of childbearing potential,\n* Sufficient cooperation and understanding to comply with the requirements of the trial,\n* Acceptance of registration in the SI-RIPH database (Système d'Information pour la Recherche sur les Produits de Santé),\n* Having received clear information and agreeing to provide written informed consent,\n* Covered by the French national health insurance system\n\nExclusion Criteria:\n\n* Hypersensitivity or history of allergy to any component of the investigational products,\n* Severe, poorly tolerated cough,\n* Complicated acute rhinitis (e.g., acute bacterial sinusitis, acute otitis media, acute bronchitis, or pneumonia),\n* Chronic or allergic rhinosinusitis,\n* Bacterial tonsillitis or pharyngitis,\n* Positive antigen test for influenza A\u002FB or COVID-19 requiring etiological treatment per current guidelines (Appendix 5),\n* Concurrent use of antitussives, bronchodilators, inhaled corticosteroids, other pulmonary-targeted therapies, or medications known to induce cough (such as ACE inhibitors, ARBs, etc.), antibiotics, antivirals, or any other treatment deemed incompatible with the study by the investigator,\n* Recent ENT surgery (\\\u003C6 months),\n* Pulmonary disease (e.g., COPD, asthma),\n* Immunodeficiency (based on patient declaration),\n* Comorbidities or a health status judged incompatible with the trial by the investigator (e.g., Gastroesophageal Reflux Disease \\[GERD\\] or abnormal lung auscultation),\n* Pregnant or breastfeeding women,\n* Regular tobacco smoker (as judged by the investigator),\n* Current participation in another clinical trial, being in an exclusion period from a previous trial, or having received total compensation exceeding 6000 euros in the 12 months prior to study start,\n* Under legal protection measures (guardianship, trusteeship, deprivation of liberty, judicial safeguard).","65 Years",{"count":163,"type":21},58,[24],"This is a post-marketing, monocentric, open-label, randomized, two-arm, parallel-group clinical study. Its primary objective is to evaluate the real-world tolerability and safety profile of two CE-marked Class I medical devices formulated as throat sprays: VB-ChSp-D-N (CDN) and VB-ChSp-W (CW), when used for symptomatic relief of cough associated with suspected viral upper respiratory infections.\n\nThe study is designed as a Category 4.2 clinical investigation according to applicable regulations, focusing on devices already bearing the CE mark and used within their intended purpose as per the manufacturer's instructions. The hypothesis is that both devices demonstrate an acceptable real-world tolerability profile, with a pre-defined threshold for adverse event incidence not to be exceeded, while also showing a positive impact on cough symptoms and patient quality of life.\n\nMethodological Framework:\n\nDesign: A two-stage Fleming design will be implemented separately for each device arm to sequentially assess the primary tolerability outcome. This design allows for an early stopping rule if an unacceptable number of adverse events is observed in the first cohort of participants.\n\nPopulation: The study will enroll adult patients (aged 18-65) presenting with an acute cough of less than three weeks' duration, attributed to a suspected viral etiology (e.g., common cold, viral pharyngitis). Key exclusion criteria are in place to ensure a population suitable for device evaluation, including the absence of underlying chronic respiratory conditions, bacterial infection, or use of prohibited medications that could confound results.\n\nIntervention: Eligible participants will be randomized in a 1:1 ratio to use either the CDN spray (n ≤ 29) or the CW spray (n ≤ 29) according to the prescribed labeling for a 7-day treatment period.\n\nAssessments: Data collection emphasizes real-world evidence capture. Participants will use an electronic daily diary throughout the treatment period to report cough symptoms (via a validated patient-reported outcome instrument), any adverse events, concomitant medications, and potential device defects (recorded as a binary yes\u002Fno occurrence). Additionally, patient-reported quality of life related to cough will be assessed using a standardized questionnaire at baseline (Day 1) and at the end of treatment (Day 8). Two on-site clinical visits (Days 1 and 8) will be conducted for clinical examination and procedures.\n\nOutcome Measures:\n\nThe study employs a hierarchical assessment of endpoints:\n\nPrimary Outcome: Tolerability\u002FSafety, defined by the incidence of device-related adverse events collected via the electronic diary.\n\nKey Secondary Outcome: Clinical Efficacy, measured by the change from baseline in the Total Cough Symptom Score (TCSS).\n\nOther Secondary Outcomes: These include the impact on cough-specific quality of life domains (sleep, daily activities, fatigue, irritability) and the incidence of device malfunctions or use errors.\n\nThe study will be conducted at a single investigational site (Clermont-Ferrand University Hospital, France).",[27],"2026-04-27",{"date":169,"type":39},"2026-04-28",{"date":171,"type":39},"2026-01-19",{"date":173,"type":21},"2027-03-31",{"name":175,"class":46},"University Hospital, Clermont-Ferrand",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":16,"minAge":183,"maxAge":184,"enrollmentInfo":185,"targetDuration":4,"studyType":139,"phases":4,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":203},"100324531","swiss-paediatric-airway-cohort-100324531","NCT03505216","Swiss Paediatric Airway Cohort","SPAC","Inclusion Criteria:\n\n* Children and adolescents aged 0-16 years\n* Resident in Switzerland\n* Seen in a paediatric pulmonary outpatient clinic due to respiratory problems\n* Parents and patients above age 14 must be able to sign an informed consent form\n\nExclusion Criteria:\n\nPrior diagnosis of cystic fibrosis, primary ciliary dyskinesia, severe heart disease, oncological disease, neuromuscular disease or severe disability","0 Years","16 Years",{"count":186,"type":21},6000,"The Swiss Paediatric Airway Cohort (SPAC) is a national, prospective clinical cohort of children and adolescents who visit physicians in Switzerland for recurrent wheeze, cough, and exercise- or sleep-related respiratory problems. SPAC aims to answer important questions on clinical phenotypes, prognosis, diagnosis and treatment. SPAC is part of routine care, and only clinically indicated investigations are done. The comprehensive baseline assessment includes a detailed questionnaire to families, plus test results, diagnoses and treatments from hospital records. Follow-up is via monthly questionnaires the first 12 months and thereafter annual questionnaires to families, and data from follow-up visits.\n\nCurrently, 4344 patients from 10 clinics and hospitals in Switzerland (Aarau, Basel, Bern, Chur, Horgen, Lausanne, Luzern, St. Gallen, Worb, Zurich) have been enrolled.\n\nSPAC provides real-life data on children visiting the Swiss health care system for common respiratory problems. It will provide a research platform for health services research, and for nested clinical and transitional studies.\n\nPublications and plain language summaries are listed on the study website: https:\u002F\u002Fwww.spac-study.ch\u002Fpublikationen\u002F",[189,190,27,191,192,193],"Asthma","Wheezing","Exercise Induced Bronchospasm","Inspiratory Laryngeal Obstruction","Dysfunctional Breathing","2026-04-16",{"date":196,"type":39},"2026-04-21",{"date":198,"type":39},"2017-06-06",{"date":200,"type":21},"2030-06-01",{"name":202,"class":46},"University of Bern",12,{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":16,"minAge":211,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":22,"phases":214,"briefSummary":215,"conditions":216,"keywords":223,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":238},"100515299","validation-of-the-c-mo-system---cough-monitoring-100515299","NCT05989698","Validation of the C-mo System - Cough Monitoring","C-mo_01","Inclusion Criteria:\n\n* Patients aged 2 years or older;\n* Patients with symptoms\u002Fcomplaints of cough;\n* Signed Informed Consent (age ≥ 18 years), signed Informed Consent from the parents\u002Flegal representative and the patient (16 and 17 years), or signed Informed Assent and Consent (5 years ≤ age ≤ 15 years).\n\nExclusion Criteria:\n\n* Presence of musculoskeletal (e.g., severe scoliosis), neurological (e.g., post stroke), cardiac (e.g., unstable angina), cognitive (e.g., dementia) changes, or other significant conditions that hinder the participants from collaborating in the collection of data.\n* Damaged\u002Fweakened skin at the C-mo wearable device's placement area (epigastric region).\n* Absence of Informed Consent and\u002For Assent, as applicable.","2 Years",{"count":213,"type":21},300,[59],"The goal of this clinical study is to validate C-mo System's ability to automatically detect and characterise cough, in patients over 2 years old with cough as a key or refractory symptom.\n\nThe main questions it aims to answer are:\n\n1. Can C-mo System detect cough events? (automatic cough detection)\n2. Can C-mo System characterise cough events? (calculation of cough intensity, identification of cough type and presence of wheeze in detected coughs)\n\nParticipants will be asked to:\n\n* Wear the C-mo Wearable device for 24 hours (1 day);\n* Complete a diary with relevant activities throughout the monitoring period;\n* Fill-out questionnaires related to coughing frequency and intensity, usability of the device, and impact of cough on quality of life.",[27,189,217,218,219,220,221,222],"Chronic Obstructive Pulmonary Disease","Gastro Esophageal Reflux","Idiopathic Pulmonary Fibrosis","Cough Frequency","Cough Severity","Coughing",[224,225,226,227],"Cough monitoring","Cough detection","Cough assessment","C-mo","2026-04-02",{"date":230,"type":39},"2026-04-08",{"date":232,"type":39},"2023-12-11",{"date":234,"type":21},"2026-09",{"name":236,"class":237},"Cough Monitoring Medical Solutions","INDUSTRY",8,{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":16,"minAge":161,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":22,"phases":249,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":4},"100625797","focused-echocardiography-for-primary-care-physicians-100625797","NCT07427303","Focused Echocardiography for Primary Care Physicians","CLINICAL FEASIBILITY OF ULTRAPORTABLE CARDIAC ULTRASOUND PERFORMED IN THE GENERAL PRACTITIONER'S OFFICE TO IDENTIFY CARDIOVASCULAR ABNORMALITIES","UPCOMING","Inclusion Criteria:\n\n* Men and women aged 65 or older with no cardiac symptoms and presenting with a treated or untreated cardiovascular risk factor (hypertension and\u002For diabetes and\u002For dyslipidemia) or\n* Adult men and women presenting with one of the following signs:\n\n  * Stage I-II exertional dyspnea\n  * Lower limb edema\n  * Unexplained fatigue\n  * Weight gain\n  * Unexplained cough\n  * History of carpal tunnel surgery (search for signs of myocardial infiltration by cardiac amyloidosis)\n\nExclusion Criteria:\n\n* Patients with arrhythmia or ventricular or supraventricular hyper excitability.\n* Symptomatic patients:\n\n  * exertional dyspnea (NYHA \\>2)\n  * palpitations\n  * malaise\n  * chest pain\n* Obese individuals with a BMI \\>35\n* Patients with breast implants\n* Patients under guardianship, conservatorship, or legal protection\n* Patients without health insurance coverage or equivalent\n* Patients known to have heart disease\n* Patients who have had a cardiology consultation within the last 5 years\n* Subjects with known heart disease, whether monitored or not.\n* Known valvular heart disease (whether monitored or not)\n* Known coronary artery disease (whether monitored or not)","120 Years",{"count":213,"type":21},[59],"Our society is characterized by a steady improvement in the standard of living of its inhabitants, which is reflected, among other things, in improved healthcare and quality of life (longer life expectancy, lower infant mortality, treatment of chronic diseases, cancer plan). Many factors contribute to this, but technological innovations and therapeutic advances are the main ones. This positive overall picture should not obscure the fact that there are significant regional disparities.\n\nFor more than 15 years, the former Lower Normandy region (Calvados, Manche, and Orne), like many other regions in France, has been marked by increasingly complex access to healthcare, whether for primary care or for so-called specialty disciplines. This situation is gradually leading to the creation of medical deserts. There are many reasons for this (numerus clausus, sociological changes, urbanization of young practitioners, attraction of small rural towns by medium-sized cities), which are chronic and have no clearly identified solution.\n\nThis situation complicates patient care and, in some cases, represents a major public health challenge, such as in the treatment of heart failure (HF), which affects more than one million people in France, or 2.3% of the adult population. For 2.3 times more deaths each year than strokes and five times more than myocardial infarctions.\n\nSome healthcare innovations can reduce the consequences of these areas of stress. In the field of cardiology, recent initiatives based on the creation of specialized cardiology and telemedicine care teams have been proposed. In primary care, point-of-care solutions enable many tests to be performed on an outpatient basis. Imaging plays a central role in patient care, and ultrasound is often the first-line modality in cardiology. Technological innovations in this field have made it possible to miniaturize ultrasound machines to such an extent that some of them can now be considered POCUS (point-of-care ultrasound). Their reduced manufacturing costs, combined with the maturity of the technique, make it possible to offer simplified acquisition protocols adapted to specific questions, known as targeted clinical ultrasound.\n\nThis simplification\u002Fminiaturization of ultrasound equipment has facilitated the spread of this technique outside the field of cardiology and now allows for its use by general practitioners close to patients, specifically for screening purposes. Many diseases would benefit from early screening in order to reduce hospitalizations, mortality, and societal costs. In cardiology, this approach remains difficult because the majority of patients admitted to healthcare facilities have already developed the disease. HF is characterized by an initial silent phase which, if left untreated, inevitably leads to complications and death. It is responsible for 200,000 hospitalizations per year in France, causing the deaths of 70,000 people. Certain signs, grouped under the French acronym EPOF, appear early on and can be warning signs, but they are often vague and unfamiliar to the general public. This fact is well illustrated by the results of a survey conducted by the Heart Failure and Cardiomyopathy Group (GICC) of the French Society of Cardiology (SFC) in 2017 (5,000 subjects representative of the French population aged 18 to 80). This survey noted that two-thirds of subjects presenting four of these signs (EPOF) had not consulted a cardiologist in the 12 months prior to the questionnaire. In the majority of cases, these patients, whether asymptomatic or paucisymptomatic (EPOF), have morphological and functional abnormalities of the heart, which are the first step toward more severe complications and can be detected by cardiac echocardiography.\n\nThere is currently a favorable alignment between echocardiography as a public health need (early detection of conditions that can lead to heart failure) and frontline practitioners (general practitioners). This alignment could lead to the definition of new practices and a new care pathway. While echocardiography is technically feasible in a general practitioner's office, its implementation remains to be evaluated (HAS report). This report emphasizes the lack of data in the literature to identify use cases and clinical impact in general medicine in France.",[252,253,254,255,256,27,257],"Age 65 and Older","Cardiac Risk Factors","Dyspnea; Cardiac","Oedema","Fatigability","Weight Gain","2026-02-16",{"date":260,"type":39},"2026-02-23",{"date":262,"type":21},"2026-03-01",{"date":264,"type":21},"2027-05-31",{"name":266,"class":46},"University Hospital, Caen",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":22,"phases":276,"briefSummary":277,"conditions":278,"keywords":283,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":47},"100624575","combined-acupressure-effects-on-post-thoracotomy-pain-and-lung-volume-100624575","NCT07411417","Combined Acupressure Effects on Post-Thoracotomy Pain and Lung Volume","The Effects of Acupressure Combination on Post-Thoracotomy Pain and Lung Volume During Rest, Breathing-Coughing Exercises: A Randomized Controlled Study","Inclusion Criteria:\n\n* Underwent thoracotomy\n* Undergoing thoracic surgery for the first time\n* Classified as ASA (American Society of Anesthesiology) physical status I, II and III\n* Presence of a drain upon admission to the intensive care unit\n* Conscious, oriented, and cooperative\n* Provided verbal and written informed consent after receiving information about the study\n\nExclusion Criteria:\n\n* Intubated\n* Persistent anxiety before the surgery\n* Diagnosed with panic disorder\n* Chemotherapy within the last 6 months\n* Diagnosed psychiatric illness or mental health problems\n* Presence of edema\n* Intraoperative or postoperative complications\n* Non-Turkish speaking, or presence of hearing or visual impairment\n* Body mass index (BMI) greater than 30\n* Participation in another clinical trial during the study period",{"count":275,"type":21},80,[59],"Pain is a subjective, sensory and emotionally unpleasant experience resulting from real or hidden injuries in tissues. The pain experience is a subjective and unique experience in physiological and psychological terms and is the first negative sensory experience of the patient after the surgical procedure. Thoracotomy is an invasive surgical incision that causes severe postoperative pain due to the negative effect on the ribs, muscles and peripheral nerves. During thoracic surgery, anatomical lung resection is performed through posterolateral thoracotomy. Surgical incision during thoracotomy surgery is the most severe cause of postoperative pain. Epidural analgesia, peripheral nerve block and systematic treatment methods are used in post-thoracotomy pain management. Opioid use is frequently preferred in post-thoracotomy pain management. Although thoracotomy pain can mostly be controlled with opioid analgesics, excessive use of opioids may lead to respiratory suppression, constipation, suppression of cough, nausea, vomiting and many other possible side effects. Ineffective postoperative pain management may lead to postoperative complications such as increased cardiac workload, prolonged pulmonary rehabilitation and delayed wound healing. The use of holistic non-drug pain relief methods is vital in reducing the need for opioid analgesics and the risk of possible side effects in early postoperative pain management.",[279,280,281,27,282],"Pain, Acute","Breathing, Mouth","Relaxation; Diaphragm","Lung Volume",[284,285,286,282],"Thoracotomy after Pain","Acupressure","Pain","2026-02-11",{"date":289,"type":39},"2026-02-13",{"date":291,"type":39},"2025-01-06",{"date":293,"type":21},"2027-01-06",{"name":295,"class":46},"Özgül Aydemir",{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":16,"minAge":303,"maxAge":304,"enrollmentInfo":305,"targetDuration":4,"studyType":22,"phases":307,"briefSummary":309,"conditions":310,"keywords":311,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":314,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":321},"100606096","phase-3-efficacy-and-safety-of-rengalin-in-the-treatment-of-arvi-cough-in-children-100606096","NCT07171099","Efficacy and Safety of Rengalin in the Treatment of ARVI Cough in Children","Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial of the Efficacy and Safety of Rengalin in the Treatment of Cough in Acute Viral Upper Respiratory Tract Infections Tract Infections in Children During the Epidemic Growth of Influenza and ARVI","Inclusion Criteria:\n\n1. Outpatients of both genders aged over 6 months and under 3 years.\n2. Clinically confirmed diagnosis of acute viral upper respiratory tract infections (acute pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, tracheitis, acute viral respiratory infection of multiple and unspecified localization) during the epidemic growth of influenza and ARVI.\n3. Dry (non-productive) cough lasting at least 24 hours but not more than 72 hours.\n4. Total (day and night) cough severity score of 6 or more.\n5. Availability of a patient information sheet and an informed consent form for participation in the clinical trial signed by one of the patient's parents\u002Fadoptive parents.\n\nExclusion Criteria:\n\n1. Presence of the following diseases at the time of inclusion in the clinical trial:\n\n   1.1 Inflammatory processes in the lower respiratory tract. 1.2 Grade III adenoid hypertrophy. 1.3 Chronic adenoiditis. 1.4 Postnasal drip syndrome. 1.5 Gastroesophageal reflux. 1.6 Bronchial asthma. 1.7 Cystic fibrosis. 1.8 Primary ciliary dyskinesia 1.9 Bronchopulmonary dysplasia 1.10 Malformations of the respiratory and ENT organs 1.11 Other chronic lung diseases. 1.12 Primary\u002Fsecondary immunodeficiency. 1.13 Oncological disease of any localization.\n2. Suspected bacterial infection of any localization, including pneumonia, sinusitis, otitis media.\n3. Allergic rhinitis.\n4. Bronchial obstruction syndrome.\n5. Acute obstructive laryngitis \\[croup\\] and epiglottitis.\n6. Congenital heart defects with hypervolemia in pulmonary circulation.\n7. Acute respiratory failure.\n8. Inflammatory, degenerative, demyelinating diseases of the central nervous system, polyneuropathies, epilepsy.\n9. Exacerbation or decompensation of chronic diseases affecting the patient's ability to participate in a clinical trial.\n10. Presence of allergy\u002Fhypersensitivity to any components of the medicines used in the treatment.\n11. Taking medications listed in the section \"Prohibited Concomitant Therapy\" within 4 weeks prior to inclusion in the study.\n12. Patients whose parents\u002Fadoptive parents, from the investigator's point of view, will not comply with observation requirements during the study or with the administration of study drugs.\n13. Participation in other clinical trials within 3 months prior to inclusion in this trial.\n14. A patient's parent\u002Fadoptive parent is related to on-site research personnel directly involved in the trial, or is the immediate family member of the investigator. 'Immediate family members' mean spouses, parents, children, or siblings, whether related or adopted.\n15. The patient's parent\u002Fadoptive parent is employed by OOO \"NPF \"MATERIA MEDICA HOLDING\", i.e., is an employee of the company, a temporary contract employee, or a designated official responsible for conducting the trial or their immediate family member.","6 Months","3 Years",{"count":306,"type":21},264,[308],"PHASE3","The goal of this clinical trial is to evaluate the efficacy and safety of liquid dosage form of Rengalin in the treatment of cough in acute viral upper respiratory tract infections infections in children in during the epidemic growth of influenza and ARVI. The main questions it aims to answer are:\n\nInvestigators will compare the liquid dosage form of Rengalin to a placebo (a look-alike substance that contains no drug) to see if Rengalin in the liquid dosage form works for cough in acute viral upper respiratory tract infections in children.\n\nParticipants will:\n\nTake the liquid dosage form of Rengalin or placebo per os 5 ml per administration 3 times a day for 7 days.",[27],[27,312,313],"Upper respiratory infection","Children from 6 months to 3 years",{"date":289,"type":39},{"date":316,"type":39},"2025-10-03",{"date":318,"type":21},"2028-12-31",{"name":320,"class":237},"Materia Medica Holding",30,{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":22,"phases":332,"briefSummary":333,"conditions":334,"keywords":339,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":352},"100615124","phase-4-a-2x2-factorial-randomized-open-label-trial-to-evaluate-neuromodulators-and-cough-control-therapy-in-patients-with-refractory-or-unexplained-chronic-cough-100615124","NCT07288528","A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough","A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough (FORTITUDE)","FORTITUDE","Inclusion Criteria:\n\n1. Adults (≥18 years old) with either:\n2. Refractory chronic cough (RCC), defined as having one or more identifiable causes of cough (asthma, allergic rhinitis, and\u002For GERD), but with previous trials of treatment targeting the underlying condition leading to no cough resolution; OR\n3. Unexplained chronic cough (UCC), defined as having a cough lasting \\>8 weeks with (i) a normal chest X-ray\u002FCT in the last 5 years and since the onset of chronic cough; (ii) FEV1 and FVC ≥80% predicted or \\>lower limit of normal (LLN); (iii) FEV1\u002FFVC ≥0.7 or \\>LLN; (iv) no evidence of asthma; and (vi) no regular symptoms of nasal\u002Freflux disease.\n\nExclusion Criteria:\n\n1. Those who, in the opinion of the investigator, have previously tried low-dose morphine, pregabalin, and\u002For CCT with full intervention fidelity for the treatment of RCC\u002FUCC;\n2. Are currently taking morphine or pregabalin for the treatment of any indication (i.e., RCC\u002FUCC or chronic pain);\\*\n3. Are currently taking other centrally-acting medication (i.e., gabapentin, amitriptyline, dextromethorphan) for the treatment of any indication (i.e., RCC\u002FUCC, seizures, or depression);\\*\n4. Have a history of opioid or substance abuse that, in the opinion of the investigator, may interfere with the conduct of the study;\n5. Are a current smoker, or ex-smoker with a \\>20 pack-year history who have abstained from smoking for \\\u003C6 months;\n6. Have cough due to angiotensin-converting enzyme inhibitor use;\n7. Have symptoms of an upper respiratory infection within the last month that have not resolved;\n8. Had an asthma exacerbation within the last month that requires an increase or start of an oral corticosteroid;\n9. Have other primary pulmonary disorders, including pulmonary embolism, pulmonary hypertension, lung cancer, cystic fibrosis, radiologically-proven emphysema, interstitial lung disease, or severe bronchiectasis;\n10. Have language, memory, cognitive, or psychiatric issues that may prevent optimal participation;\n11. Have creatinine clearance \\\u003C15 mL\u002Fmin, including individuals with end-stage renal disease who require hemodialysis or peritoneal dialysis;\n12. Have any other condition that, in the opinion of the qualified investigator, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant;\n13. Have participated in another clinical trial of an investigational medicinal product within 30 days;\n14. Pregnant or breastfeeding; or\n15. Females of child-bearing potential who:\n\n    1. Do not agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of 3 months.\n    2. Acceptable methods of birth control include oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormone implant, double-barrier method, intrauterine devices, non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s), vasectomy of partner at least 6 months prior to screening.\n    3. Females who are not of child-bearing potential will be defined as females who have undergone a sterilization procedure (e.g., hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening.\n\n       * Participants taking any of the above medications at baseline will only be eligible if they are willing and medically able to safely discontinue them at least 2 weeks prior to the first study visit. Eligibility will be confirmed by the local study investigator prior to enrolment.",{"count":331,"type":21},124,[24],"The FORTITUDE trial will provide head-to-head evidence on the benefits and harms of two commonly prescribed neuromodulators (low-dose morphine and pregabalin), the effectiveness of a virtual cough control therapy, exploratory assessment of potential synergy in combining these interventions, and the long-term outcomes of these treatments in patients with refractory or unexplained chronic cough.",[27,335,336,337,338],"Refractory Chronic Cough","Unexplained Chronic Cough","Cough Hypersensitivity Syndrome","Chronic Cough",[27,338,340,341,342,335,336],"Morphine","Pregabalin","Non-Pharmacologic Therapy","2025-12-04",{"date":345,"type":39},"2025-12-17",{"date":347,"type":21},"2026-04-01",{"date":349,"type":21},"2029-07-01",{"name":351,"class":46},"McMaster University",5,{"id":354,"slug":355,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":55,"sex":16,"minAge":360,"maxAge":18,"enrollmentInfo":361,"targetDuration":4,"studyType":139,"phases":4,"briefSummary":363,"conditions":364,"keywords":365,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":375},"100567569","validation-of-a-questionnaire-to-measure-cough-severity-100567569","NCT06669897","Validation of a Questionnaire to Measure Cough Severity","Validation of a Questionnaire to Measure Cough Severity in Patients With Chronic Cough","Inclusion Criteria:\n\n* Aged between 30 and 99 years\n* Clinical diagnosis of chronic cough or healthy volunteers\n* Good understanding of Spanish\n\nExclusion Criteria:\n\n* Non-Spanish-speaking patients\n* Inability to complete the questionnaires\n* Failure to sign the informed consent form","30 Years",{"count":362,"type":21},100,"To design and validate a questionnaire that allows objective assessment of the severity of chronic cough",[27],[27,90],"2025-09-09",{"date":368,"type":39},"2025-09-15",{"date":370,"type":39},"2025-05-01",{"date":372,"type":21},"2026-04",{"name":374,"class":46},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",6,{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":11,"sex":16,"minAge":107,"maxAge":383,"enrollmentInfo":384,"targetDuration":4,"studyType":22,"phases":386,"briefSummary":387,"conditions":388,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":398},"100575502","phase-3-phase-iii-trial-of-susu-zhike-granules-in-children-with-cold-cough-syndrome-for-acute-cough-treatment-100575502","NCT06773117","Phase III Trial of Susu Zhike Granules in Children With Cold-cough Syndrome for Acute Cough Treatment","Efficacy\u002FSafety of Susu Xiao'er Zhike Granules for Children's Cold-Induced Cough (Wind-Cold Syndrome): Multicenter, Randomized, Double-Blind, Low-Dose Controlled Phase III Trial","Inclusion Criteria:\n\n1. It met the diagnostic criteria for common cold, and the severity VAS score of day or night cough was ≥40 mm ，the cough symptom score was ≥2 points;\n2. Conforming to the standard of wind-cold cough differentiation;\n3. Age 6-13 years old (6 years old ≤ age \\\u003C 14 years old);\n4. Duration of cough ≤48 hours;\n5. Maximum axillary temperature ≤38℃ within 24 hours before diagnosis;\n6. The informed consent process should be in accordance with the regulations, and the legal guardian or the subject child (≥8 years old) should sign the informed consent.\n\nExclusion Criteria:\n\n1. accompanied by pharyngeal swelling pain, heat image is obvious;\n2. White blood cell count, neutrophils absolute value, C-reactive protein, all exceeded the upper limit of 1.2 times the reference value, and the researchers considered the bacterial infection;\n3. there have been complications (bacterial otitis media, sinusitis, suppurative tonsillitis, bronchitis, bronchopneumonia);\n4. Patients with acute bronchitis and pneumonia cured less than 8 weeks;\n5. People with a history of seasonal or perennial allergic rhinitis, chronic sinusitis, chronic otitis media, bronchial asthma, chronic cough or recurrent respiratory infections;\n6. Other acute episodes of nasal diseases (vasomotor rhinitis, drug rhinitis, etc.), nasal foreign body, or foreign body inhalation, any anatomical respiratory abnormalities;\n7. Patients with serious systemic diseases or mental disorders such as cardiovascular, brain, liver, kidney and hematopoietic system;\n8. Those who had used Chinese and Western drugs and therapies that had influence on the effectiveness evaluation of the experimental drugs within 24 h before enrollment;\n9. Allergic to known components of the investigational drug;\n10. Those who participated in other clinical trials and took investigational drugs within the past one month;\n11. Those who were not considered suitable for inclusion by the researchers.","13 Years",{"count":385,"type":21},360,[308],"To confirm the effect of Susu Xiaoer Zhike granules in treating cough caused by common cold (wind-cold cough Syndromes) in children aged 6\\~13 years, shortening the course of disease and improving symptoms.",[27],"2025-08-14",{"date":391,"type":39},"2025-08-19",{"date":393,"type":21},"2025-09-01",{"date":395,"type":21},"2027-12-31",{"name":397,"class":237},"Tasly Pharmaceutical Group Co., Ltd",19,{"id":400,"slug":401,"hasResults":11,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":405,"eligibilityCriteria":406,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":407,"enrollmentInfo":408,"targetDuration":4,"studyType":22,"phases":410,"briefSummary":411,"conditions":412,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":422,"locationsCount":47},"100592910","phase-4-the-mechanism-versus-ppi-trial-100592910","NCT06999577","The Mechanism Versus PPI Trial","The MVP Trial: A Randomized Controlled Trial of Mechanism Guided vs PPI Strategy for Laryngopharyngeal Reflux","MVP","Inclusion Criteria:\n\n1. 18-89 years of age\n2. \\>8 weeks of laryngeal symptoms (cough, throat clearing, dysphonia)\n3. Standard evaluation for LPR, undergoing EGD (with endoscopic evaluation of the hypopharynx) and reflux monitoring off acid suppression\n4. Off acid suppression therapy for at least 2 weeks prior to randomization.\n\nExclusion Criteria:\n\n1. PPI intolerance and\u002For known hypersensitivity to the formulation or substituted benzimidazoles\n2. History of foregut surgery\n3. Known diagnosis of achalasia\n4. Inability to fast for 4 hours (no food or drink)\n5. Active tobacco use\n6. Pregnant or breastfeeding\n7. Unable to consent in English or Spanish\n8. Unable to provide consent without a legal guardian or representative\n9. Imprisoned\n10. Endoscopic findings conclusive with esophageal mucosal abnormalities\n11. Unable to proceed with reflux monitoring\n12. Use of acid suppression during the reflux monitoring and\u002For before the study medication (omeprazole or placebo) is dispensed\n13. Prior LRT for reflux related symptoms\n14. History of major psychiatric comorbidity\n15. Unable to attend in person study visits at UCSD","89 Years",{"count":409,"type":21},160,[24],"The goal of this clinical trial is to learn if a mechanism guided strategy that utilizes a multidisciplinary approach to treat adults patients (age 18-89) with chronic throat symptoms who are undergoing clinical evaluation for laryngopharyngeal reflux (LPR) is more effective than the usual care strategy with proton pump inhibitor (PPI) therapy used in gastroenterology for these patients.\n\nThe main question it aims to answer is: Will a greater proportion of the mechanism guided strategy participants achieve symptom response in comparison to the usual care strategy participants?\n\nIf there is a comparison group: Researchers will compare the mechanism guided strategy to usual care strategy to see if treatment response differs between the groups.\n\nParticipants will be be asked to do the following:\n\n* participate in an 8-week blinded study phase where they will be randomized to either 1) Mechanism Guided Strategy or 2) Usual Care Strategy\n* take an oral capsule daily (omeprazole 40mg or placebo)\n* come to 3 in-person visits at UC San Diego Health for an intervention visit with a study provider\n* consider incorporating recommended lifestyle modifications\n* complete weekly surveys",[413,27,414,66,415],"Laryngopharyngeal Reflux","Throat Clearing","Reflux","2025-07-29",{"date":418,"type":39},"2025-08-01",{"date":420,"type":39},"2025-06-04",{"date":349,"type":21},{"name":423,"class":46},"University of California, San Diego",{"id":425,"slug":426,"hasResults":11,"nctId":427,"briefTitle":428,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":22,"phases":432,"briefSummary":433,"conditions":434,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":4},"100597674","objective-evaluation-of-cough-effort-in-tracheotomized-patients-lost-study-100597674","NCT07061561","Objective Evaluation of Cough Effort in Tracheotomized Patients (LOST Study)","Inclusion Criteria:\n\n* Adult patients (18 years or older)\n* Hospitalized in post-intensive care rehabilitation unit (SRPR) or intensive care unit (ICU)\n* Tracheotomized during the weaning process\n* Medical prescription for physiotherapy assessment\n* Medical prescription for speech therapy assessment\n\nExclusion Criteria:\n\n* Patients who have undergone total laryngectomy\n* Patients with severe swallowing disorders\n* Patients with cognitive impairments incompatible with understanding instructions\n* Patients under medical decision to stop active treatments\n* Patients who refuse to participate or refuse to sign informed consent\n* Patients under guardianship or curatorship\n* Patients not affiliated with a social security scheme",{"count":431,"type":21},34,[59],"This study aims to evaluate how well tracheotomized patients can cough before and after their tracheostomy tube is removed. Cough strength is measured using two different tools-Peak Flow and Lorio. Researchers want to find out if the cough measurement taken before removing the tube can help predict how effective the patient's cough will be afterward. The study will also explore factors that might influence cough strength and compare the usefulness of the two tools. Additionally, it will assess how patients feel about using these devices and the role of diaphragm ultrasound in predicting cough effectiveness.",[435,27,436,437,438],"Tracheostomy","Weaning","Respiratory Function Tests","Diaphragm","2025-07-02",{"date":441,"type":39},"2025-07-11",{"date":443,"type":21},"2025-07-15",{"date":445,"type":21},"2026-11-15",{"name":447,"class":46},"Centre Hospitalier de Saint-Denis",{"id":449,"slug":450,"hasResults":11,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":454,"eligibilityCriteria":455,"healthyVolunteers":11,"sex":16,"minAge":456,"maxAge":457,"enrollmentInfo":458,"targetDuration":4,"studyType":22,"phases":459,"briefSummary":460,"conditions":461,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":47},"100591339","phase-3-dexmedetomidine-magnesium-sulphate-and-lidocaine-for-cough-suppression-after-general-anesthesia-100591339","NCT06979141","Dexmedetomidine, Magnesium Sulphate and Lidocaine for Cough Suppression After General Anesthesia","Comparative Study Between Efficacy of Dexmedetomidine, Magnesium Sulphate and Lidocaine for Cough Suppression During General Anesthetic Emergence","MgSO4\u002FDEX","Inclusion Criteria:\n\n* Aged 21-60 years.\n* Both genders.\n* Body mass index \\\u003C 30 kg\u002F m2\n* American Society of Anesthesiology (ASA) physical status I-II.\n* Mallampati score class I or II.\n* Patients undergoing surgery under general anesthesia.\n\nExclusion Criteria:\n\n* Known allergy to study drugs.\n* History of psychiatric illness.\n* Patients with major organ diseases.\n* Pre-existing neurological deficits.\n* Body mass index \\>30 kg\u002Fm2.\n* Active airway infection or history of tracheal and laryngeal surgery.\n* Lower esophageal sphincter incompetence (and reflux).\n* Increased intracranial and intraocular pressure.\n* Use of cough-inducing medications\n* Pregnant, and lactating women.","21 Years","60 Years",{"count":213,"type":21},[308],"The aim of this prospective randomized controlled double-blinded study is to compare the efficacy of dexmedetomidine, MgSO4 and lidocaine for cough suppression during general anesthetic emergence as regard number and severity.",[27],"2025-06-07",{"date":464,"type":39},"2025-06-11",{"date":466,"type":39},"2025-06-02",{"date":468,"type":21},"2026-08-01",{"name":470,"class":46},"Al-Azhar University",{"id":472,"slug":473,"hasResults":11,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":4,"eligibilityCriteria":477,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":478,"targetDuration":480,"studyType":139,"phases":4,"briefSummary":481,"conditions":482,"keywords":486,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":47},"100583583","cough-and-hemorrhoids-100583583","NCT06878209","Cough and Hemorrhoids","Is Cough a Predisposing Factor for Hemorrhoids? A Prospective, Analytical Study","Inclusion Criteria:\n\n1. Being 18 years of age or older\n2. Speaking and understanding Turkish\n3. To be mentally and cognitively capable of understanding the questions asked\n4. To agree to participate in the research\n5. individuals diagnosed with hemorrhoidal disease\n\nExclusion Criteria:\n\n1. Those with existing proctologic disease other than hemorrhoidal disease and pelvic floor disease\n2. Patients with previous surgery for hemorrhoidal disease\n3. Patients with hemorrhoidal disease caused by portal hypertension\n4. Patients during pregnancy and diagnosed with postpartum hemorrhoidal disease\n5. those with benign prostatic hyperplasia or neurogenic bladder that may cause increased intra-abdominal pressure",{"count":479,"type":21},134,"1 Day","The aim of the study is to investigate the relationship between hemorrhoids and cough by assessing the symptoms, duration, and severity of cough in patients who will present to the general surgery outpatient clinic of Muğla Education and Research Hospital (MERH) with symptoms such as bleeding, pain, itching, fecal leakage, prolapse, and mucus discharge. These patients will be diagnosed with hemorrhoidal disease through rectal examination to detect anal pathology and will be graded according to mucosal prolapse. Our study will aim to determine whether cough is a predisposing factor for hemorrhoids by evaluating the presence, duration, and frequency of cough symptoms in patients with hemorrhoids. The study will be designed as a cross-sectional, analytical, and descriptive study. Between March 2025 and June 2025, patients with newly diagnosed hemorrhoids who will present to the MEAH General Surgery Outpatient Clinic will undergo physical examinations and will be assessed for cough symptoms. Evaluations will include height and weight measurements, the Leicester Cough Questionnaire, the Cough Visual Analog Scale (VAS) questionnaire, duration of cough (categorized as acute if shorter than 4 weeks, or chronic if longer than 4 weeks), timing of cough (day, night, or all day), comorbidities (such as COPD, asthma, chronic bronchitis, interstitial lung disease, idiopathic pulmonary fibrosis, and others), and smoking history (active, former, or never smoked). The primary endpoint will be to compare the relationship between the severity of hemorrhoids and the duration and frequency of cough in patients with both conditions. The secondary endpoint will be to compare the grade of hemorrhoids with comorbid chest diseases in these patients. The tertiary endpoint will be to compare the degree of hemorrhoids with the smoking history of patients who have both hemorrhoids and cough.",[483,27,484,220,221,485],"Hemorrhoid","Cough Duration","Hemorrhoids, Internal",[487],"cough, hemorrhoid","2025-05-08",{"date":490,"type":39},"2025-05-11",{"date":492,"type":39},"2025-03-14",{"date":494,"type":21},"2025-10-14",{"name":496,"class":46},"Muğla Sıtkı Koçman University",{"id":498,"slug":499,"hasResults":11,"nctId":500,"briefTitle":501,"officialTitle":502,"acronym":503,"eligibilityCriteria":504,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":505,"enrollmentInfo":506,"targetDuration":507,"studyType":139,"phases":4,"briefSummary":508,"conditions":509,"keywords":510,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":518,"completionDateStruct":519,"leadSponsor":521,"locationsCount":47},"100586698","development-of-a-cough-control-questionnaire-ccq-100586698","NCT06918756","Development of a Cough Control Questionnaire (CCQ)","The Development and Validation of a Cough Control Questionnaire","CCQ","Inclusion Criteria:\n\n* Adult patients aged 18 and over with acute and chronic cough (including refractory chronic cough and unexplained chronic cough) and able to read and write in English. A smaller number (n =20) of healthy volunteers will also be included with no evidence of significant respiratory disease.\n\nExclusion Criteria:\n\n* Current smokers (or smoking within the last 12 months), respiratory tract infection within the last 4 weeks, use of angiotensin converting enzyme inhibitors (ACEi), and pregnancy","100 Years",{"count":362,"type":21},"7 Years","Chronic cough (\\>8 weeks in duration) affects 5-12% of the global population, and is associated with considerable health status impairment and comorbidities. Currently, there are validated severity and impact outcome measures whilst objective measures with cough frequency monitoring is not available in routine clinical practice. Unlike other chronic respiratory diseases, namely asthma, there are no validated dedicated tools to assess the control of cough as a disease.\n\nThis study aims to develop a validated patient-focused tool to assess the control of cough, which may be useful to evaluate the benefit and value of treatments in both clinical and research settings.",[27],[511,512,513,514],"patient-reported outcomes","cough","control","questionnaire","2025-04-01",{"date":517,"type":39},"2025-04-09",{"date":515,"type":39},{"date":520,"type":21},"2031-09-01",{"name":522,"class":46},"King's College Hospital NHS Trust",{"id":524,"slug":525,"hasResults":11,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":4,"eligibilityCriteria":529,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":530,"enrollmentInfo":531,"targetDuration":4,"studyType":22,"phases":533,"briefSummary":534,"conditions":535,"keywords":539,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":549,"locationsCount":551},"100421383","a-non-pharmacological-cough-control-therapy-100421383","NCT04767074","A Non-pharmacological Cough Control Therapy","A Non-pharmacological Cough Control Therapy as an Adjuvant of Pulmonary Rehabilitation in People With Interstitial Lung Diseases and Chronic Cough - A Feasibility Study","Inclusion Criteria:\n\n* Individuals will be included if having confirmed diagnosis of any ILD by a physician (as per Canadian Thoracic Society's guideline for evaluating patients with fibrotic interstitial lung disease) and a chronic cough lasting more than 8 weeks in duration\n\nExclusion Criteria:\n\n* self-reports of moderate or large sputum production\n* effective or suspected exacerbation of the respiratory condition in the past month\n* upper respiratory tract infection in the past month\n* use of angiotensin-converting enzyme inhibitor medication\n* changes in the prescribed medication in the previous month\n* evidence of traction bronchiectasis in the HRCT\n* evidence of other medical conditions that prevent performance of an exercise training program\n* unable to read or speak in English \u002F unable to provide informed consent.","85 Years",{"count":532,"type":21},24,[59],"Coughing affects almost all individuals with ILD leading to physical, psychological and social distress and prevents individuals from performing their activities of daily living, working or socialising in public places. Unfortunately, there are no licensed medications available to treat chronic cough and the few drugs that have been tried resulted in little efficacy and significant side effects. Drug-free cough control interventions have shown promise in reducing the severity and impact of coughing on patients' lives but have not been tested in individuals with ILD. This study aims to explore the feasibility and effectiveness of a non-pharmacological cough control therapy, as an adjuvant of pulmonary rehabilitation, in patients with ILD and chronic cough (\\>8 weeks in duration).",[27,536,537,538],"ILD","Pulmonary Disease","Pulmonary Fibrosis",[27,536,540,143,541],"Pulmonary rehabilitation","non-pharmacological cough therapy","2025-03-28",{"date":544,"type":39},"2025-04-03",{"date":546,"type":39},"2020-09-01",{"date":548,"type":21},"2025-12",{"name":550,"class":46},"West Park Healthcare Centre",2,{"id":553,"slug":554,"hasResults":11,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":4,"eligibilityCriteria":558,"healthyVolunteers":55,"sex":16,"minAge":17,"maxAge":161,"enrollmentInfo":559,"targetDuration":4,"studyType":22,"phases":560,"briefSummary":561,"conditions":562,"keywords":564,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":47},"100293896","phase-4-sensory-mechanical-responses-to-eucapneic-voluntary-hyperventilation-and-mannitol-100293896","NCT03105843","Sensory-Mechanical Responses to Eucapneic Voluntary Hyperventilation and Mannitol","Sensory-Mechanical Responses to Eucapneic Voluntary Hyperventilation and Mannitol in Individuals With Cough Variant Asthma and Chronic Cough","Inclusion Criteria:\n\n* Individuals aged 18-65 years of age with CVA and individuals with methacholine-induced cough but normal airway sensitivity. The following definitions will be used:\n\n  1. CVA: chronic cough (≥8 weeks) is the sole or predominant symptom and positive methacholine challenge (PC20 ≤ 16 mg\u002FmL) and history of cough responding to specific asthma treatment (such as inhaled steroid or 1 week trial of bronchodilator);\n  2. Methacholine-induced cough but normal airway sensitivity: chronic cough (≥8 weeks) is the sole or predominant symptom and negative methacholine challenges (PC20 \\> 16 mg\u002FmL).\n* Individuals aged 18-65 years of age with no history of asthma or chronic cough.\n\nExclusion Criteria:\n\n* an exacerbation necessitating a change in medication, emergency department visit or hospitalizations within the previous 4 weeks\n* inability to perform acceptable spirometry\n* medical contraindications to methacholine challenge testing\n* smoking history in excess of 10 pack years Note: Previous treatment with inhaled or systemic corticosteroids is not an exclusion criterion; medication use will be recorded and examined in the analysis.",{"count":321,"type":21},[24],"The objectives of this study are to determine the sensory-mechanical responses to Eucapneic Voluntary Hyperventilation (EVH) and Mannitol in individuals with cough variant asthma (CVA) and methacholine-induced cough with normal airway sensitivity (COUGH) and compare these responses to a control group of healthy individuals without asthma or chronic cough.\n\nWe hypothesize:\n\n1. EVH and Mannitol cause dyspnea, cough, small airway obstruction with resultant dynamic hyperinflation, gas trapping and autoPEEP in individuals with CVA and COUGH, but not healthy controls.\n2. The sensory-mechanical responses to both hyperosmolar challenges (EVH and Mannitol) are comparable within groups (CVA, COUGH and healthy controls).",[189,27,563],"Cough Variant Asthma",[189,27,565,566],"Eucapneic Voluntary Hyperventilation","Hypertonic Saline","2025-03-17",{"date":569,"type":39},"2025-03-20",{"date":571,"type":39},"2022-03-01",{"date":573,"type":21},"2026-06-30",{"name":575,"class":46},"Dr. Diane Lougheed",{"id":577,"slug":578,"hasResults":11,"nctId":579,"briefTitle":580,"officialTitle":580,"acronym":4,"eligibilityCriteria":581,"healthyVolunteers":11,"sex":16,"minAge":304,"maxAge":17,"enrollmentInfo":582,"targetDuration":4,"studyType":139,"phases":4,"briefSummary":583,"conditions":584,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":599,"locationsCount":47},"100531568","prospective-multicentre-study-on-symptoms-in-first-onset-bronchial-asthma-in-children-and-adolescents-100531568","NCT06201494","Prospective Multicentre Study on Symptoms in First-onset Bronchial Asthma in Children and Adolescents","Inclusion Criteria:\n\n\\- Child 3 - 18 years old, first evaluation in pulmonary outpatient clinic for any of the following respiratory symptoms: cough, shortness of breath, chest tightness, wheezing, recurrent lower respiratory tract and lung infections, dyspnoea of any type, pathological listening findings.\n\nExclusion Criteria:\n\n* Other documented chronic respiratory, cardiovascular, neurological, genetic, infectious, metabolic disease, significant immaturity or other disease that may be accompanied by respiratory symptoms.",{"count":275,"type":21},"Bronchial asthma may present with symptoms other than the commonly reported complaints (cough, chest tightness, shortness of breath and wheezing). Less common symptoms include chronic or recurrent productive cough, inspiratory dyspnoea or recurrent pneumonia. Children presenting with these symptoms are often diagnosed with asthma bronchiale and benefit from antiasthmatic management.",[189,585,586,27,587,190,588,589,590,591,592],"Asthma in Children","Dyspnea","Pneumonia","Shortness of Breath","Chest Tightness","Lower Respiratory Tract and Lung Infections","Recurrent Respiratory Tract Infections","Mucus; Plug","2024-06-14",{"date":595,"type":39},"2024-06-18",{"date":597,"type":39},"2023-01-01",{"date":123,"type":21},{"name":600,"class":46},"Charles University, Czech Republic"]